Know Cancer

or
forgot password

A Randomized Study Evaluating the Efficacy of the Synthetic Adhesive Solution Ifabond, in Reducing Seroma Formation Post Surgery in Breast Cancer Patients, When Used in Partial Mastectomy With or Without Axillary Lymph Node Dissection


N/A
18 Years
N/A
Open (Enrolling)
Female
Breast Cancer, Lymphocele

Thank you

Trial Information

A Randomized Study Evaluating the Efficacy of the Synthetic Adhesive Solution Ifabond, in Reducing Seroma Formation Post Surgery in Breast Cancer Patients, When Used in Partial Mastectomy With or Without Axillary Lymph Node Dissection


Breast cancer patients will be selected at their preoperative visit with the surgeon, who
will inform them about the study and answer their questions.

Patients who consent to participate will be randomized to one of two arms:

1. Arm A: Applying Ifabond

2. Arm B: Without Ifabond

Patients will be stratified according to these two criteria:

1. Axillary Lymph Node Dissection planned (ALND)

2. Body Mass Index (BMI)

The following parameters will be measured:

- ECOG status and Blood Pressure at day 3(day 7 in case of ALND), day 15 and day 30 post
surgery

- Volume of drainage at day 3 and at (day 7 in case of ALND)post surgery

- Discomfort alleged by the patient at day 3(day 7 in case of ALND), day 15 and day 30
post surgery

- Lymphocele volume measured by ultrasound at day 15 and day 30 post surgery

- If the volume is ≥ 100cc, a needle aspiration will be performed, and the volume of
aspirate will be documented.

- Adverse events and concomitant medications will be collected throughout the study until
30 days after the last ultrasound.


Inclusion Criteria:



- "Eastern Cooperative Oncology Group" ECOG status ≤ 2

- Diagnosis of invasive or In situ breast cancer

- Patient undergoing partial mastectomy with or without axillary lymph node
dissection,(without communication between the two surgical loges)

Exclusion Criteria:

- Pregnant or breast-feeding patient

- Participation at another protocol with an Investigational drug (within the last 4
weeks before enrollment)

- Known hypersensitivity to Cyanoacrylate

- Known hypersensitivity to formaldehyde

- Patient who experience systemic infections preoperatively, or have conditions that
are known to interfere with the healing process

- Patient with uncontrolled diabetes

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care

Outcome Measure:

Change in seroma formation

Outcome Description:

The volume of drain at Day 3 (or 7 in case of axillary lymph node dissection) post surgery will be documented, then patients will have an ultrasound exam at day 15 and day 30 (+or- 2 days) to measure seroma.

Outcome Time Frame:

Day 3 (or 7 in case of axillary lymph node dissection), day15 and day 30 post surgery

Safety Issue:

No

Principal Investigator

Michel CONTE, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hôpital Ambroise Paré, Marseille

Authority:

France: ANSM (Agence nationale de sécurité du médicament et des produits de santé)

Study ID:

RCB ID: 2011-A01014-37

NCT ID:

NCT01742975

Start Date:

November 2011

Completion Date:

January 2015

Related Keywords:

  • Breast Cancer
  • Lymphocele
  • Breast Neoplasms
  • Lymphocele

Name

Location